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Malaria has become a major public health problem in Mauritania since the 1990s, with an average of 181,000 cases
per year and 2,233,066 persons at risk during 1995–2012. This paper provides the first publicly available overview of
malaria incidence and distribution in Mauritania. Information on the burden and malaria species distribution is
critical for guiding national efforts in malaria control. As the incidence of malaria changes over time, regular
updates of epidemiological data are necessary.
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The Islamic Republic of Mauritania is situated in north-
west Africa between 15 and 27° N latitude and 5 and 17°
W longitude. It occupies a total surface area of 1,030,700
sq km (Figure 1). The population of Mauritania is cur-
rently estimated to be 3,378,250 inhabitants [1] (Table 1).
Population pyramid shows that nearly 43.7% are under
15 years old [2]. Infant mortality rate is 77.0 per 1,000
live births [2]. The Mauritanian population belongs to
several ethnic groups: Moors (including ‘white Moors’
and ‘black Moors’) and black Africans (Poular, Wolof,
and Soninke). However, there are no data on the demo-
graphic weight of each ethnic group. Sedentarization
and rural exodus, partly related to the periods of
drought in the 1970s and 1980s, are the most significant
demographic phenomena that have occurred in
Mauritania since the country’s independence in 1960.
Whereas the proportion of urban population was 9% in
1965, it increased to 22.7, 46.7 and 60% in 1977, 2005
and 2010, respectively. Over the same period, the nomad
population rapidly decreased from 65% in 1965 to 12
and 6% in 1988 and 2000, respectively [3]. Since its inde-
pendence in 1960, Mauritania has experienced intense
migratory movements. Outward flows started in the* Correspondence: alimedsalem@gmail.com
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These early flows were mainly directed towards sub-
Saharan African countries, such as Senegal, Mali, Ivory
Coast, and Gambia. Inward flows, coming mainly from
neighbouring countries (Senegal, Mali, Guinea Conakry,
and Ivory Coast), consisted of labour migration which
filled the needs of the labour market. The total number
of regular immigrants in 2010 was estimated to be
99,229, corresponding to 3% of the total resident popula-
tion [4]. A large inward flow of refugees and asylum
seekers due to civil conflicts in African countries (i.e.
Liberia, Sierra Leone, Ivory Coast, and Mali) occurred in
the 1990s. Currently, Mauritania hosts 93,590 refugees,
including 66,400 Malian refugees, who left their country
due to the most recent conflict in Mali [5]. Within the
last decade, Mauritania has also evolved into an import-
ant transit country, attracting irregular migrants from
sub-Saharan African countries attempting to enter into
Europe through the Canary Islands, Ceuta, and Melilla.
Two-thirds of the surface area of Mauritania is cov-
ered by the Sahara Desert and one-third is sub-Saharan
semi-desert. It has a low annual rainfall that increases
from north to south, one rainy season from June/July to
September/October, depending on the year and/or
region, and a dry season (‘cold dry season’ between
November to March and ‘hot dry season’ from March to
June). Accordingly, the country is geographically divided
into three ecological areas (Figure 2): arid Saharan zone
in the north, Sahelian zone in the intermediate regionentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 Map of Mauritania with its 13 provinces.
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The arid zone covers the land surface below 150 mm
isohyets. It corresponds to the Saharan climate charac-
terized by the presence of several oases that have been
established for centuries, mainly in Adrar and Tagant re-
gions. The Sahelian zone, made up of steppe and
savannah grassland, is characterized by annual rainfall of
100–300 mm. In this region, the inhabitants practice
animal breeding and rain-fed agriculture. The Senegal
River Valley region, sometimes known as Shemama, is aTable 1 Population demographic data of Mauritania
Indicator Value Reference
Population density (inhabitant/sq km) 3.4 [1]
Urban population (%) 60 [2]
Gender
Male (%) 50.2 [2]
Female (%) 49.6 [2]
Age groups (%)
<15 years 43.7 [2]
15-65 years 51.0 [2]
>65 years 5.3 [2]
Birth rate (%) 4.6 [2]
Mortality rate (%) 1.3 [2]
Infant mortality (%) 7.7 [2]
Growth rate 2.4 [2]
Life expectancy at birth (years) 57.5 [2] Figure 2 Major agro-climatic zone of Mauritania.
Figure 4 Distribution of Plasmodium spp. based on microscopy
in Mauritania.
Lekweiry et al. Malaria Journal  (2015) 14:100 Page 3 of 8narrow belt of land that extends north and east of the
Senegal River. Rainfall is higher than in other regions,
ranging from 300–500 mm annually. This rainfall, com-
bined with annual flooding of the river, provides the
basis for agriculture with a potential farmland estimated
at 135,000 hectares. The main and most important per-
manent water source in Mauritania is the Senegal River
that runs along the southwestern common border with
Senegal.
Malaria distribution and causative agents
The history of documented malaria cases in Mauritania
is relatively recent. The official statistics, mostly based
on clinical diagnosis without laboratory confirmation,
show an increase of malaria cases during the last two
decades from 26,933 in 1990 to 165,834 in 2012 [6] with
an average of 181,000 cases per year (Figure 3). The
disease is currently the leading cause of morbidity and
mortality and the first cause of consultation and
hospitalization in eight of 13 regions of the country. In-
deed, during the transmission season (August-November),
60% of hospital admissions are due to presumptive diag-
nosis of malaria, which represents, on average, 25% of
morbidity and over 39% of mortality at health facilities [7].
Moreover, malaria is considered the third motive of
outpatient consultations at national level, after acute
respiratory infections and diarrhoea [7].
Studies conducted in different regions reported the
presence of four malaria species in Mauritania (Figure 4),
namely Plasmodium falciparum, Plasmodium vivax,
Plasmodium ovale, and Plasmodium malariae [8-12].
Plasmodium falciparum was the dominant species, diag-
nosed in 90% of reported clinical malaria cases. The
recorded infection rates were variable depending on the
season, region and rainfall. In the first published report
from the southern region of Gorgol, Sautet et al. [8]
reported 180 positive malaria cases among 307 febrile
patients, corresponding to a malaria prevalence rate ofFigure 3 Number of reported malaria cases from 1990 to 2012 in Ma59%. Plasmodium falciparum was detected in 133
(43.3%) of 307 examined slides, followed by P. malariae
with (10.7%) and P. vivax (4.5%). In another study con-
ducted in southern Mauritania, Escudie and Hamon [13]
reported two human malaria species with a predomin-
ance of P. falciparum over P. malariae. Three years later,
a survey conducted in the cities of Atar in northern
Mauritania and Kaedi, Kiffa, Kankoussa, Aioun, and
Tamchakett in southern Mauritania, noted the presence
of only P. falciparum and P. malariae, with an infection
rate of 7% [10]. The sero-prevalence of malaria was also
studied in schoolchildren throughout the country. It re-
vealed a sero-prevalence of 8%, indicating a recenturitania.
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(Saharan part of the country), 58% in Boutilimit (Sahelian
region), and 34-45% in the Sahelian region of Assaba re-
gion. The survey also reported a malaria serological preva-
lence of 12% in March 1973 (during the dry season) and
14% in November 1972 (just after the rainy season) among
schoolchildren in Nouadhibou, a coastal city in northwest-
ern Mauritania [14]. In a survey conducted in 1984, one
year following the construction of Foum Legleita Dam in
the Gorgol region, Baudon et al. [15] reported a very low
level of anti-malarial antibodies using indirect immuno-
fluorescence. Of the surveyed population, 73% had anti-
malarial antibody titres of less than 1/40 and only 4% of
them displayed antibodies titres of 1/640 or above.
More recently, studies conducted in Nouakchott, the
capital city of Mauritania, showed that infection due to
malaria has increased with a high rate of infection due
to P. vivax. In 2003, Cortes et al. [11] found 77 positive
slides out of 446 blood smears collected from febrile pa-
tients attending health facilities in Nouakchott. Malaria
infection rate was 18.5% (77/446), with 61.8% due to P.
falciparum and 35.5% due to P. vivax. The authors also
found nine malaria cases (seven due to P. falciparum
and two due to P. vivax), which were considered as
autochthonous. Moreover, Mint Lekweiry et al. [12]
reported a malaria prevalence of 25.7% (61/237) among
febrile patients attending three health facilities in
Nouakchott in 2007. The majority of these cases were
due to P. vivax (43/61, 70.5%), followed by P. ovale (15/
61, 24.6%) and P. falciparum (3/61, 4.9%) by microscopy.
PCR performed on these samples confirmed all P. vivax
and P. falciparum infections, but cases initially diag-
nosed to be P. ovale infections by microscopy turned out
to be P. vivax by PCR. Therefore, after PCR correction,
the proportion of P. vivax to P. falciparum was 58/61
(95.1%), and no P. ovale or P. malariae malaria parasites
were detected by PCR. This study also revealed that
among 237 recruited febrile patients, 231 were clinically
diagnosed and treated as malaria cases and that false
positive constituted 73.6% of the clinically diagnosed
malaria. This finding highlights the importance of the
timely use of microscopy and, in case of unavailability of
microscopes and/or well-trained microscopists, an
alternative reliable laboratory tool, in particular rapid
diagnostic tests for malaria, will play a major role in
establishing the correct diagnosis and appropriate
treatment.
In the follow-up study performed in 2009–2010, the
same authors found a malaria prevalence of 34.9% (105
of 301 febrile patients) among children born and resid-
ing permanently in Nouakchott [16]. Among these
patients with malaria confirmed by microscopy, rapid
diagnostic test and PCR, 102 of 105 (97.1%) infections
were due to P. vivax and 2.9% (three of 105) werecaused by P. falciparum. The results of this 2009–
2010 study confirmed malaria prevalence among fe-
brile patients and distribution of Plasmodium spp. in
Nouakchott. Moreover, 54 of the P. vivax-infected
children had never travelled outside Nouakchott, sug-
gesting that malaria transmission occurs within the
city and that P. vivax is the principal causative agent.
In general, while malaria diagnosis, based on thick and
thin smears, previously reported the presence of four
malaria species in the country [8-11], more recent data
obtained using nested PCR showed the presence of only
P. vivax and P. falciparum in Nouakchott and southern
Mauritania [12,16,17]. Furthermore, malaria affects all
age groups in the country [7,11]. However, data on mor-
bidity and mortality associated with this disease are
underestimated due to limited health information and
insufficient resources to confirm diagnosis with micros-
copy (or rapid diagnostic test for malaria) in most health
centres. Most febrile patients tend to practice self-
medication for fever at home or prefer consulting private
health sectors, for which there are no health data in the
country. It is worth noting that despite the publication
of several papers demonstrating P. vivax endemicity in
Nouakchott, the World Malaria Report 2013 erroneously
indicates that Mauritania is free of P. vivax, demonstrat-
ing a gap in the quality of national data submitted to
WHO [6].
Population structure and drug resistance of malaria
parasites
In 1991, during the survey of anti-malarial drug resist-
ance in West Africa, Guiguemde et al. [18] reported that
only Mauritania is still spared from chloroquine resist-
ance. Three years later, chloroquine-resistant P. falcip-
arum was detected in the autochthonous Mauritanian
population. Gasquet et al. [19] investigated clinical re-
sponse to chloroquine among 37 febrile patients infected
with P. falciparum attending the health facility in Kiffa
(Assaba region) with the following characteristics: a
minimum parasite density of 1,000 asexual parasites/μl
of blood, absence of chloroquine in the urine, and no
recent history of treatment with other anti-malarial
agents. The patients received a standard dose of 25 mg
base of chloroquine per kg body weight over three days
and were followed until day 7. Six patients were lost to
follow-up. Three (9.7%) of the 31 enrolled patients had
recurrent asexual parasitaemia, and one patient
remained febrile on day 7, suggesting clinical resistance
to chloroquine.
Jelinek et al. [20] combined a clinical study on chloro-
quine efficacy, conducted in 1998, with an analysis of
molecular markers for drug resistance, P. falciparum
chloroquine resistance transporter (pfcrt) and P. falciparum
multidrug-resistance gene 1 (pfmdr1), after an unusually
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Clinical chloroquine resistance was detected in 33 of 85
(38.8%; 19 (22.3%) RI resistance and 14 (16.5%) RII/RIII re-
sistance) P. falciparum-infected patients followed until day
14. Molecular analysis showed a sensitivity for detection of
clinical resistance of 60.6% and a specificity of 65.3% for
pfmdr1 76-tyrosine mutant allele while Lys76Thr mutation
in pfcrt gene showed a very high sensitivity (100%) but low
specificity (65.4%) to detect clinical resistance. The combin-
ation of mutations in both genes decreased the sensitivity
to 60.6% while specificity increased to 76.9%. The authors
concluded that pfcrt, but not pfmdr1, may be useful to
monitor chloroquine resistance in Mauritania.
Molecular analysis of resistance to antifolates (pyri-
methamine and sulphadoxine) was performed by Eberl
et al. [21] using the same blood samples collected in
Aioun and Kobeni in an earlier study [20]. These
authors examined 162 P. falciparum isolates collected in
Hodh Elgharbi region (southeast Mauritania) from
patients recruited at two medical centres in Aioun, the
regional capital city and Kobeni, a small city near the
border with Mali, for point mutations in dihydrofolate
reductase (dhfr) (codons 16, 51, 59, 108, and 164) and
dihydropteroate synthase (dhps) genes (codons 436, 437,
540, 581 and 613). Dhfr mutations were found at a low
prevalence both in Aioun and Kobeni (18.6% of samples
from Aioun and 12.6% of samples from Kobeni showed
at least one mutation), whereas a high prevalence of
dhps mutations was noted among isolates from Aioun
(74.6%) and Kobeni (63.4%), respectively. These results
suggested that sulphadoxine-pyrimethamine may be
effective for intermittent preventive treatment in preg-
nant Mauritanian women (the only current indication of
sulphadoxine-pyrimethamine in Mauritania), but more
clinical data are required to confirm the molecular
findings.
In 2012, Mint Lekweiry et al. [22] reported a low
prevalence of mutants in the P. vivax population isolated
from 110 malaria-infected patients in Nouakchott.
Indeed, the majority of the isolates (n = 100, 90.9%) were
genotyped as wild-type P. vivax dhfr (pvdhfr), while the
remaining ten isolates carried the Ser58Arg and Ser117Asn
double mutations (homologues of Cys59Arg and
Ser108Asn in P. falciparum dhfr). All isolates had the
wild-type P. vivax dhps (pvdhps) alleles. For P. vivax
multidrug resistance gene 1 (pvmdr1), 75 of 103 (73%)
had the wild-type Tyr976, and 28 (27%) carried the mutant
Phe976. Most (98%) carried the mutant Leu1076 codon.
Of 105 isolates, 102 (97%) had one gene copy and three
(3%) had two copies of the pvmdr1 gene. Pvmdr1 mu-
tations have been suggested to be associated with
chloroquine resistance in P. vivax, whereas an in-
creased number of copy number has been associated
with resistance to mefloquine [23,24].Studies on the genetic structure of Plasmodium spp.
populations in Mauritania are very limited. Jordan et al.
[17] genotyped 173 P. falciparum isolates, collected in
Aioun and Kobeni in 1998 as part of the clinical study
on chloroquine efficacy, for three polymorphic genetic
markers: merozoite surface protein 1 (msp1) and mero-
zoite surface protein 2 (msp2), and glutamate-rich pro-
tein (glurp). The differences in the population structure
between the two study areas were seen in both the mean
number of distinct parasite populations per infection
(1.57 for Aioun and 2.34 for Kobeni) and their distribu-
tion in different allelic groups. For msp2, the differences
in the number of size variations and amplified fragments
were observed in the msp2 FC27 allelic family. Isolates
from Aioun showed one or two bands with six different
sizes, while amplification of the samples from Kobeni
produced up to four bands with 18 different band sizes.
However, analysis of glurp provided no further conclu-
sive information because all samples showed a single
band of the same size, suggesting limited heterogeneity
of P. falciparum populations circulating in this region.
More recently, Ould Ahmedou Salem et al. [25] exam-
ined and compared the genetic diversity of msp1 block 2
region among P. falciparum isolates in Nouakchott, the
capital city of Mauritania, and Hodh Elgharbi region
(southeast of Mauritania). K1, Mad20 and Ro33 msp1
alleles were identified with 27 different sized alleles.
Infection with multiple P. falciparum populations was
observed in the two regions (93/113; 82.3%), as well as a
high multiplicity of infection (3.2 genotypes per infection),
reflecting both the high endemicity level and malaria
transmission in the study areas.
Malaria vectors
The first published studies on malaria vectors date back
to the 1940s [8], followed by those of Maffi [26] and
Hamon et al. [27]. These authors reported the presence
of the following 12 Anopheles species and subspecies in
Mauritania: Anopheles funestus, Anopheles gambiae s.l.,
Anopheles pharoensis, Anopheles rufipes, Anopheles
melas, Anopheles dhtali, Anopheles rhodesiensis, Anoph-
eles coustani, Anopheles ziemmani, Anopheles pretorien-
sis, Anopheles squamosus, and Anopheles demilloni.
Among these anopheline species, only An. gambiae and
An. funestus are known to be major malaria vectors in
Africa. In Mauritania, An. gambiae s.l. appears to be the
dominant malaria vector [8,28]. However, until today,
their distribution in the country has not been established
(Table 2).
Recently, Dia et al. [28] studied the distribution, host
preference and infection rates of three malaria vectors,
Anopheles arabiensis, An. pharoensis and An. funestus, in
21 localities in five regions in Mauritania, namely Trarza,
Brakna, Assaba, Hodh Elgharbi and Tagant. They collected
Table 2 Distribution of the Anopheles gambiae complex
and Anopheles funestus group in Mauritania
Region Anopheles sp. Reference
Adrar No data
Assaba An. arabiensis; An. gambiae;
An. gambiae s.l. and An. funestus
[26-28]
Brakna An. gambiae1; An. gambiae s.l. and
An. funestus
[8,29]
Gorgol An. gambiae s.l. and An. funestus [8]
Guidimaka An. gambiae s.l. [27]
Hodh Echargui An. gambiae s.l. [27]
Hodh Elgharbi An. gambiae [28]
Inchiri No data
Nouadhibou No data
Nouakchott An. arabiensis; An. gambiae s.l. [29,12,30]
Tagant An. gambiae s.l. [28]
Trarza An. gambiae s.l. and An. funestus [28]
Tiris zemmour No data
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was the most commonly identified species (92%), followed
by An. pharoensis (5%) and An. funestus (3%). Anopheles
gambiae was collected in all localities except in Moudjeria
(north of the country) where there was no mosquito cap-
tured during the study period. The molecular identification
of the An. gambiae complex revealed the predominance of
An. arabiensis and the presence of An. gambiae (M form)
in Assaba, Brakna and Hodh Elgarbi regions. In
Nouakchott, the presence of anopheline mosquitoes (An.
gambiae s.l.) was first reported in Toujounin district [29].
More recently, Mint Lekweiry et al. [12] demonstrated the
presence of An. arabiensis and An. pharoensis in Dar Naim
district in Nouakchott. Ould Ahmedou Salem et al. [30]
have recently shown, for the first time, the existence of An.
gambiae s.l. larval habitats in Nouakchott and described
their ecological and physico-chemical characteristics. They
reported that water bodies consisting of water discharged
from standpipes and household drinking water tanks served
as Anopheles spp. larval habitats. Using multivariate regres-
sion analyses, it was further shown that salinity up to 0.1
g/l and shaded habitats were protective factors against high
larvae density in breeding sites and that pH up to 7.61 was
a risk factor to develop high larvae density in these breed-
ing sites. However, studies on bionomics, epidemiology of
anopheline species, and their involvement in malaria trans-
mission remain poorly understood although the presence
of P. falciparum and P. vivax sporozoites was demonstrated
in the salivary glands of An. arabiensis collected in
Mauritania [28,31].National malaria control programme: policy strategy and
plans
The Mauritanian Ministry of Health executes malaria
control through the National Malaria Control Programme,
which has elaborated a quadrennial strategic plan against
malaria epidemics and endemicity. The stated goal of the
latest plan for 2011–2015 is to reduce, by 2015, malaria-
related morbidity and mortality from 17.5% and 0.39 per
100,000 inhabitants in 2011 to 10.9% and 0.15 per 100,000
inhabitants in 2015, respectively [2]. The strategies for
achieving this goal are based on the establishment of a
monitoring system, early detection of malaria epidemics,
reliable laboratory-based diagnosis and appropriate and
effective treatment of malaria cases, a system of preven-
tion of and appropriate response to malaria epidemics,
and collection of factual evidence on malaria epidemics.
The promotion and distribution of insecticide-treated bed
nets (ITNs) among populations living in endemic areas,
particularly during the transmission season, the use of
sulphadoxine-pyrimethamine for intermittent preventive
treatment (IPT) to control malaria during pregnancy,
particularly during the first and second pregnancies, are
the main objectives of this strategy.
As of 2014, ITNs have been distributed free of charge
to the major risk groups in southern Mauritania, i.e.
among pregnant women, and IPT has been effectively
implemented since 2008 [32]. However, intradomiciliary
residual spraying and larval control have not been rec-
ommended by the Mauritanian National Malaria Control
Programme. Laboratory diagnosis of malaria is free of
charge for febrile patients of all ages in the public sector
and is mainly based on the use of rapid diagnostic test,
and not microscopy, due to the shortage of microscopes
under working condition and well-trained microscopists.
In addition, it is recommended for travellers visiting
endemic areas in the south to use chemoprophylaxis
(atovaquone-proguanil, doxycycline or mefloquine) starting
from ten to 21 days before departure, during their stay and
three weeks following their return from these regions [33].
Furthermore, a national malaria day has been organized
annually since 1996 by the Ministry of Health to inform
and educate the public about the importance and risks of
malaria.
It is worth noting that in 2006, following the emergence
of chloroquine-resistant P. falciparum in West Africa,
particularly in the Senegal River Basin, the Mauritanian
Government decided to replace chloroquine with
artemisinin-based combination therapy (ACT). This policy
change was principally based on clinical studies conducted
in Senegal and extrapolated to the Mauritanian situation.
Regardless of the parasite species involved, the treatment
of uncomplicated malaria is currently based on artesunate-
amodiaquine as the first-line treatment, artemether-
lumefantrine as the second choice, and quinine as the
Lekweiry et al. Malaria Journal  (2015) 14:100 Page 7 of 8third-line drug [7]. Monotherapies using artemisinin deriv-
atives have been withdrawn, and ACT is provided free of
charge to laboratory-confirmed malaria-infected patients
of all ages in the public sector. For the treatment of P.
vivax malaria, the National Malaria Control Programme
recommends the use of primaquine for radical treatment if
glucose-6-phosphate dehydrogenase (G6PD) test is normal.
This drug policy has not yet been implemented in the field.
As part of future prospective studies aiming to develop an
evidence-based national anti-malarial drug policy, the
National Malaria Control Programme and the University
of Sciences, Technology and Medicine in Nouakchott have
been collaborating since 2012 to conduct clinical studies in
several sentinel sites in the country to validate and, if
needed, modify the current anti-malarial treatment
guidelines.
Conclusion
Mauritania faces several challenges in the management
of malaria, including limited financial resources, crisis in
human resources, shortage of health workers and health
structures with reliable diagnostic facilities, insufficient
epidemiological data on parasite distribution and malaria
vectors, and regular epidemics. Entomological studies
are currently being conducted at several sentinel sites in
different epidemiological strata in the country to capture
and collect mosquito larvae and adults, identify predom-
inant Anopheles spp. in each study site, characterize
physico-chemical factors in the breeding sites, determine
whether adult female Anopheles mosquitoes are infect-
ive, and assess their sensitivity to insecticides. In parallel,
malaria burden and drug resistance are being assessed in
these sentinel sites to determine the prevalence of
laboratory-confirmed malaria among febrile patients and
their response to ACT. Research capacity building and
training of laboratory technicians and general practi-
tioners are integral parts of these on-going field activ-
ities. The introduction of ACT is another challenge
facing Mauritania. One of the key issues is the cost of
ACT, which is 20 times higher than the cost of conven-
tional therapy, such as quinine ($2.44 per adult dose).
Population migration from sub-Saharan endemic coun-
tries constitutes another challenge where no official mea-
sures for controlling malaria prevalence among these
migrants exist. Mauritania still does not have a reliable
database on malaria epidemiology. A nationwide malaria
indicator survey is being planned to fill this gap in 2015.
Updated information and maps on malaria burden and
Plasmodium species distribution are critical for guiding
national efforts to improve laboratory diagnosis, imple-
ment rapid and effective treatment, and coordinate and
plan malaria elimination from the country in the near
future. As malaria incidence changes over time, regular
updates of epidemiological data are necessary.Abbreviations
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